[go: up one dir, main page]

CO5280078A1 - Compuestos - Google Patents

Compuestos

Info

Publication number
CO5280078A1
CO5280078A1 CO01024184A CO01024184A CO5280078A1 CO 5280078 A1 CO5280078 A1 CO 5280078A1 CO 01024184 A CO01024184 A CO 01024184A CO 01024184 A CO01024184 A CO 01024184A CO 5280078 A1 CO5280078 A1 CO 5280078A1
Authority
CO
Colombia
Prior art keywords
sub
compounds
chr
pharmaceuticals
cycloalkyl
Prior art date
Application number
CO01024184A
Other languages
English (en)
Inventor
John David Harling
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5280078A1 publication Critical patent/CO5280078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo: <EMI FILE="01024184_1" ID="1" IMF=JPEG >en la que R1 es naftilo o fenilo opcionalmente susti tuido con uno o más sustituyentes seleccionados entre el grupo que consiste en halo, -O-alquilo C1-6, -S-alquilo C1-6, alquilo C1-6, haloalquilo C1-6, -O- (CH2)n-Ph, -S-(CH2)nPh, ciano, fenilo y CO2R en donde R es hidrógeno o alquilo C1-6 y n es 0, 1, 2 ó 3; o R1 es fenilo condensado con un anillo cíclico aromático o no aromático de 5-7 miembros, en donde dicho anillo cíclico contiene opcionalmente hasta tres he teroátomos, independientemente seleccionados entre N, O y S;R2 es H, alquilo C1-6, alcoxi C1-6, fenilo, NH(CH2)n-Ph, NH-alquilo C1-6, halo o alcoxi;R3 es COOH, tetrazol, CN, NO2, OH, -S-alquilo C1-6-, -SO-alquilo C1-6, -O-alquilo C1-6, SONH2, CHO, CH2OH, (CH2)nNH2, CONHOR´, O(CH2)nCO2R´, O(CH2)nCONHR´, CONHR´, (CH2)nCO2R´, o (CH2)nCONHR´, en donde R´es hidrógeno o alquilo C1-6 y n es 0, 1, 2 ó 3; yuno de X1 y X2 es N o CR'' y el otro es NR'' o CHR´´ en donde R´´ es hidrógeno, alquilo C1-6, cicloalquilo C3-7; o cuando de X1 y X2 es N o CR´´ entonces el otro puede ser S u O; con la condición de que el compuesto no es uno en el que R1 sea naftilo o fenilo opcionalmente sustituido n uno o más sustituyentes seleccionados entre el grupo que consiste en halo, -O-alquilo C1-6, -S-aquilo C1-6, alquilo C1-6, -O-(CH2)nPh, -S-(CH2)nPH, ciano, fenilo y CO2R en donde R es hidrógeno o alquilo C1-6 y n es 0, 1 , 2 ó 3; o R1 es fenilo condensado con un anillo ciclico aromático o no aromático de 5-7 miembros en donde dicho anillo cíclico contiene opcionalmente hasta dos heteroátomos, independientemente seleccionados entre N, O y S;y R2 es H, NH (CH2)n-Ph o NH-alquilo C1-6;y R3 es CO2H, CONH2, CN, NO2, alquiltio C1-6, SO2-alquilo C1-6, alcoxi C1-6, SONH2, CONHOH, NH2, CHO, CH2OH, CH2NH2 o CO2R en donde R es hidrógeno o alquilo C1-6.
CO01024184A 2000-03-27 2001-03-27 Compuestos CO5280078A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007405.4A GB0007405D0 (en) 2000-03-27 2000-03-27 Compounds

Publications (1)

Publication Number Publication Date
CO5280078A1 true CO5280078A1 (es) 2003-05-30

Family

ID=9888509

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01024184A CO5280078A1 (es) 2000-03-27 2001-03-27 Compuestos

Country Status (9)

Country Link
US (1) US6906089B2 (es)
EP (1) EP1268465B1 (es)
JP (1) JP2003528870A (es)
AT (1) ATE296821T1 (es)
AU (1) AU4257901A (es)
CO (1) CO5280078A1 (es)
DE (1) DE60111205D1 (es)
GB (1) GB0007405D0 (es)
WO (1) WO2001072737A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039198A1 (en) * 2000-11-16 2004-02-26 Bender Paul E. Compounds
ES2237671T3 (es) * 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
CZ20032691A3 (en) 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
CZ303808B6 (cs) 2001-05-24 2013-05-09 Eli Lilly And Company Nové pyrazolové deriváty jako farmaceutická cinidla
GB0127430D0 (en) * 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
JP2005539000A (ja) * 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
ES2274302T3 (es) 2002-08-09 2007-05-16 Eli Lilly And Company Benzimidazoles y benzotiazoles como inhibidores de la map quinasa.
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
ATE433968T1 (de) * 2002-09-18 2009-07-15 Pfizer Prod Inc Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
EA200500354A1 (ru) 2002-09-18 2005-10-27 Пфайзер Продактс Инк. Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
CA2499332A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
EA200500376A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Триазольные производные в качестве ингибиторов трансформирующего фактора роста (tgf)
BR0314302A (pt) 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1556373A1 (en) * 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2006217801A (ja) * 2003-01-15 2006-08-24 Kirin Brewery Co Ltd ＴＧＦβ阻害活性を有する化合物の新規用途
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
RU2005134670A (ru) * 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
JP4853284B2 (ja) 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
KR100749566B1 (ko) * 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
WO2006025988A1 (en) * 2004-07-29 2006-03-09 Schering-Plough Ltd. Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CA2686318A1 (en) * 2007-05-04 2008-11-13 Jana Pickova Compound feed for aquaculture
BRPI0811317A2 (pt) 2007-08-03 2015-01-27 Summit Corp Plc Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
BRPI0909288A2 (pt) * 2008-03-14 2015-08-18 Otsuka Pharma Co Ltd Inibidores da mmp-2 e/ou da mmp-9
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
MX2010010317A (es) * 2008-03-21 2010-10-04 Novartis Ag Compuestos heterociclicos novedosos y usos de los mismos.
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
EP2476672A1 (en) 2010-12-22 2012-07-18 Momentive Specialty Chemicals Research Belgium S.A. Glycidyl esters of alpha , alpha branched acids compositions
CA2841252C (en) 2011-07-13 2019-02-26 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
SG11201407635XA (en) 2012-05-30 2014-12-30 Univ Cornell Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
AU2014218807A1 (en) 2013-02-22 2015-09-03 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
EP3387112A4 (en) 2015-12-07 2019-08-21 BioTime, Inc. METHOD FOR RECONNECTING BROWN FAT CELLS DERIVED FROM VARIOUS PLURIPOTENT STEM CELLS
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
FI3618875T3 (fi) 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
EP3894401A2 (en) 2018-12-11 2021-10-20 Theravance Biopharma R&D IP, LLC Naphthyridine and quinoline derivatives useful as alk5 inhibitors
EP3897689B1 (en) 2018-12-21 2025-02-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
JP2023502662A (ja) 2019-11-22 2023-01-25 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
WO2022013307A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
MX2023000519A (es) 2020-07-15 2023-02-13 Chiesi Farm Spa Derivados de pirido-oxazina-amino como inhibidores de alk5.
EP4182322B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
WO2022136221A1 (en) 2020-12-23 2022-06-30 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CA3232178A1 (en) 2021-09-21 2023-03-30 Daniela PIZZIRANI Pyridazinyl amino derivatives as alk5 inhibitors
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH561717A5 (es) * 1971-05-10 1975-05-15 Ciba Geigy Ag
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
US5955480A (en) 1996-11-20 1999-09-21 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
WO1998021957A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JPH11180958A (ja) * 1997-12-24 1999-07-06 Yamanouchi Pharmaceut Co Ltd 新規アミン誘導体
JP2002541253A (ja) * 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール

Also Published As

Publication number Publication date
WO2001072737A1 (en) 2001-10-04
EP1268465A1 (en) 2003-01-02
ATE296821T1 (de) 2005-06-15
US6906089B2 (en) 2005-06-14
GB0007405D0 (en) 2000-05-17
EP1268465B1 (en) 2005-06-01
US20030149277A1 (en) 2003-08-07
JP2003528870A (ja) 2003-09-30
DE60111205D1 (de) 2005-07-07
AU4257901A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
CO5280078A1 (es) Compuestos
CO5031285A1 (es) Triarilimidazoles
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
PT1204323E (pt) Fungicidas
NO20074657L (no) Nitrogenholdige aromatiske ringforbindelser
WO2001077107A8 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
PH12009500610A1 (en) 4-imidazolin-2-one compounds
CA2316902A1 (en) Alpha-aminoamide derivatives useful as analgesic agents
SE0004245D0 (sv) Novel compounds and their use
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
AU2001266575A1 (en) Chemical compounds
WO2001012202A3 (en) Use of chemical chelators as reversal agents for drug-induced neuromuscular block
DE69505470D1 (de) Pyrrolocarbazol
DE60228990D1 (de) Bicyclische verbindung
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
WO2003031414A1 (en) Novel heterocyclic compound and anti-inflammatory agent
ATE330958T1 (de) Pyrazino 1&#39;2&#39;:1,6öpyrido 3,4-böindolderivate
MX9206930A (es) Nuevos compuestos
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DE60216948D1 (en) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
ID30435A (id) Proses-proses untuk menyiapkan perantara-perantara pestisidal
AU5390900A (en) Potassium channel blocking agents
ATE275572T1 (de) Malto-oligosaccharid-derivate und ihre anwendungen

Legal Events

Date Code Title Description
FC Application refused